• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis and Ulster University initiate new partnership
Share
Announcements, News

ProAxsis and Ulster University initiate new partnership

June 29, 2020
-
Posted by David Ribeiro

ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, has formed a new partnership with Ulster University, the largest university in Northern Ireland.  The company will be collaborating on an initial 12-week project with the Eastern Corridor Medical Engineering (ECME) mini-projects scheme, which supports the development of industrially relevant platform technologies. 

The project will involve significant interaction between ProAxsis and the University, and is targeted at utilising the extensive specialist expertise of the University team to drive enhancements to the company’s existing portfolio of products. The ECME Programme, including the Mini Projects, are funded by the European Union’s Interreg VA Programme which is managed by the Special EU Programmes body (SEUPB).

Speaking about the plans, Dr David Ribeiro, CEO of ProAxsis, said:

“The ECME lead partner, Ulster University, has a long-standing and successful heritage of creating value from their knowledge base, so we’re absolutely delighted to have the opportunity to work with them on the ECME Mini Projects, which we believe will produce highly commercially beneficial outputs.  We look forward to announcing updates on this collaborative project in the near future.”

Professor Jim McLaughlin, Head of the School of Engineering at Ulster University and also Programme Director for ECME added:

“We were very impressed by the response to the ECME COVID-19 Call both in terms of the number of applications received but also the readiness of the applicant companies to respond swiftly to the COVID-19 pandemic.   We strongly believe that the awards will help target the local and national response to the pandemic but also lead to longer term economic impact across the region, especially in the development of new products, platforms and expertise that will eventually be harnessed for future development beyond COVID-19.”

ABOUT PROAXSIS

ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis.  

This technology has been translated in to a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels.  Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months. 

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.

Aside from the provision of assays, ProAxsis is able to offer sample analysis at its purpose-built laboratory facility in Belfast, and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

ProAxsis is one of the core portfolio companies of Netscientific plc.  The company is also supported by QUBIS, the commercialisation arm of the Queens University Belfast.

ABOUT ECME

The Eastern Corridor Medical Engineering Centre (ECME) is a collaborative research project focusing on improving cardiovascular health.  It is a partnership between five leading academic research centres, Ulster University, Dublin City University, University College Dublin, University of the Highlands and Islands, Dundalk Institute of Technology and the Southern Health & Social Care Trust.

ECME is funded by the European Union’s InterregVA Programme which is managed by the Special EU Programmes body (SEUPB).  The €283m INTERREG VA Programme is one of 60 similar funding programmes across the European Union that have been designed to help overcome the issues that arise from the existence of a border.  These issues range from access to transport, health and social care services, environmental issues and enterprise development.

For more information on ECME, please visit www.ecme-research.com

June 29, 2020

Related News

Other posts that you should not miss.
News

ProAxsis Limited recognised as Gold Level Innovator by Innovate NI

December 2, 2020
-
Posted by David Ribeiro

ProAxsis (www.proaxsis.com), the Belfast-based protease diagnostics company, is delighted to announce that it has been recognised as …

Read More
December 2, 2020
Posted by David Ribeiro
Announcements, Neutrophil Elastase Immunoassay, News

ProAxsis investing in R&D to create new diagnostic tests for chronic human diseases

July 27, 2020
-
Posted by David Ribeiro

Belfast based respiratory diagnostics company, ProAxsis is investing over £200,000 in R&D to enhance its novel ProteaseTag® …

Read More
July 27, 2020
Posted by David Ribeiro
News

ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife

January 31, 2022
-
Posted by Jessica Robinson

ProAxsis Limited, the Belfast-based diagnostics company, today announces an expansion of its activities in Asia, via a …

Read More
January 31, 2022
Posted by Jessica Robinson
← PREVIOUS POST
ProAxsis and the Connected Health Innovation Centre launch new partnership
NEXT POST →
ProAxsis announces new appointments
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis and Ulster University initiate new partnership - ProAxsis